Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751488 | 0.91 | JAK2 (0.49) | GPR119ALKHPGDJAK2JAK1 | |
| SCHEMBL30751518 | 0.89 | MAPT (0.44) | ALKHPGDUSP2MAPTALOX15 | |
| SCHEMBL30751553 | 0.88 | GPR119 (0.53) | GPR119JAK2JAK1TYK2PDE4D | |
| SCHEMBL30751541 | 0.88 | GPR119 (0.53) | GPR119JAK2JAK1TYK2PDE4D | |
| SCHEMBL30751548 | 0.85 | TYK2 (0.46) | GPR119JAK1TYK2 | |
| SCHEMBL30751495 | 0.84 | PTPN11 (0.52) | GPR119ALKHPGDUSP2MAPT | |
| SCHEMBL30751486 | 0.82 | GPR119 (0.46) | GPR119MAPTNPSR1PTPN11JAK2 | |
| SCHEMBL30751545 | 0.82 | GPR119 (0.46) | GPR119MAPTNPSR1PTPN11JAK2 | |
| SCHEMBL31673033 | 0.80 | MAP4K1 (0.51) | HPGDUSP2MAPTALOX15TSHR | |
| Hydrochloric Acid SCHEMBL31673016 | 0.79 | BRPF1 (0.45) | ALKHPGDUSP2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | GPR119 604/4885ALK 809/4885HPGD 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.